Spero Therapeutics (SPRO) Non-Current Deferred Tax Liability (2024 - 2025)
Spero Therapeutics posted quarterly Non-Current Deferred Tax Liability of $388000.0 for Q4 2025, down 52.45% year-on-year from $816000.0 in Q4 2024, and down 52.45% on a QoQ basis from $816000.0 in Q4 2024.
Spero Therapeutics (SPRO) has 2 years of Non-Current Deferred Tax Liability data on file, last reported at $388000.0 in Q4 2025.
- For the quarter ending Q4 2025, Non-Current Deferred Tax Liability fell 52.45% year-over-year to $388000.0; the trailing twelve-month figure through Dec 2025 stood at $388000.0 (down 52.45% YoY), and the FY2025 full-year result was $388000.0, down 52.45% from the prior year.
- Non-Current Deferred Tax Liability for Q4 2025 stood at $388000.0, down from $816000.0 in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $816000.0 in Q4 2024 and bottomed at $388000.0 in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Spero Therapeutics | 162.39 Mn | 106.26 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 388,000.00 |
| Dec 31, 2025 | 388,000.00 |
| Dec 31, 2024 | 816,000.00 |
| Dec 31, 2024 | 816,000.00 |